The overall treatment experience with the current practice patterns is favourable, with only 12% of patients developing permanent kidney failure despite C5 inhibitor therapy and no increased risk of poor long-term kidney function outcomes in patients in whom treatment is electively discontinued. The gene discussed is C5; the disease is kidney failure.